Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting

Rhea-AI Summary

Windtree Therapeutics (OTCID: WINT) announced stockholder approval of ten key proposals at their Special Stockholder Meeting on August 28, 2025. The company is pivoting towards environmental services and revenue generation, abandoning previously considered cryptocurrency treasury plans.

Key approvals include proposals for environmental services transactions aimed at revenue generation, and an increase in authorized shares from 125 million to 1 billion. The company plans to partner its biotech assets, potentially eliminating $8.8 million in R&D expenses from 2024 related to its cardiovascular program.

The strategic shift focuses on establishing the Windtree Environmental Services division with potential for profitability through future acquisitions.

Positive

• Stockholder approval for all ten strategic proposals indicates strong shareholder support
• Potential elimination of $8.8 million in R&D expenses through biotech asset partnerships
• Strategic pivot to revenue-generating environmental services business
• Increased financial flexibility with authorized shares expansion from 125M to 1B

Negative

• Abandonment of cryptocurrency treasury strategy indicates strategic uncertainty
• Significant dilution potential with authorized shares increase to 1 billion
• Company transitioning away from core biotech business, indicating previous strategy wasn't successful

The Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders

The stockholder approved proposals provide the foundation for Windtree revenue generating deals in environmental services

Windtree is choosing to focus on environmental services and other revenue generating businesses – the Company will not move forward with the cryptocurrency treasury strategy

Company continues to move forward with potential deals for both biotech assets that will bring in near term cash and long term milestones and royalties

WARRINGTON, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that key proposals for its corporate strategy were approved at the Special Stockholder Meeting on August 28, 2025.

The proxy voting reached a quorum prior to the meeting date and all ten of the proposals were approved by stockholder proxy voters. Two proposals were related to the environmental services company transaction planned by the Company. That transaction will provide a path to revenue generation and the opportunity to add additional environmental services companies for scale. The corporate plan targets potential profitability for the Windtree Environmental Services division when a future acquisition is completed.

Another key area for the Company approved by stockholders is planning for growth through potential deals by increasing authorized shares from 125 million to 1 billion. Flexibility of financial instruments that could utilize equity is provided by this stockholder approved proposal.

To ensure we are focused on our core strategy and as previously stated by the Company, it plans to find partnership for the cardiovascular and oncology biotech assets for continued development. In 2024, Windtree had $8.8 million of expense for research and development (R&D) related to the cardiovascular program. The Company believes that a partnership could eliminate further R&D expenses.

The Company believes that focusing on its new core business will be beneficial for its stockholders. The Company has chosen not to move forward with the cryptocurrency treasury strategy.

“We thank our stockholders for supporting our strategic plan in their proxy voting,” said Jed Latkin, Chief Executive Officer of Windtree. “Our forward-looking plan to generate revenue and future profit with our assets is underway and we are making progress every day. We believe that focusing on our new core business will be beneficial to our stockholders. As such, we have chosen not to move forward with the cryptocurrency treasury strategy and we hope to successfully partner our biotech assets in the near term, which will eliminate R&D expenses which were nearly $9 million in 2024. We look forward to providing updates on this Company transformation.”

About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a diversified company with several divisions and focused on becoming a revenue generating company with future profitability.

Forward Looking Statements
The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: risks related to the Company’s ability to begin its environmental services business, wind down the crypto currency strategy, and manage costs and execute on its operational and budget plans. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact Information:
Eric Curtis
ecurtis@windtreetx.com

FAQ

What key proposals did Windtree Therapeutics (WINT) stockholders approve in August 2025?

Stockholders approved all ten proposals, including environmental services company transactions and an increase in authorized shares from 125 million to 1 billion. The approvals support the company's pivot to revenue-generating environmental services.

How much could Windtree Therapeutics save by partnering its biotech assets?

Windtree could eliminate $8.8 million in R&D expenses related to its cardiovascular program, which was the cost incurred in 2024.

What is Windtree Therapeutics' new business strategy for 2025?

Windtree is pivoting to focus on environmental services and revenue-generating businesses, while seeking partnerships for its biotech assets and abandoning previously considered cryptocurrency treasury plans.

Why did Windtree Therapeutics increase its authorized shares to 1 billion?

The increase in authorized shares provides greater financial flexibility for potential deals and growth through equity-based financial instruments.

What happened to Windtree Therapeutics' cryptocurrency strategy?

The company has chosen not to move forward with the previously considered cryptocurrency treasury strategy, focusing instead on environmental services and revenue generation.